 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics, Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index NASDAQ: NBI. Repares addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ 